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Abstract  
Dietary sodium intake is associated with hypertension and cardiovascular risk 
in the general population. In patients with chronic kidney disease, sodium 
intake has been associated with progressive renal disease, but not 
independently of proteinuria. We studied the relationship between urinary 
sodium excretion and urinary sodium:creatinine ratio and mortality or 
requirement for renal replacement therapy in chronic kidney disease.  Adults 
attending a renal clinic who had at least one 24-hour urinary sodium 
measurement were identified. 24-hour urinary sodium measures were 
collected and urinary sodium:creatinine ratio calculated. Time to renal 
replacement therapy or death was recorded. 423 patients were identified with 
mean estimated glomerular filtration rate of 48ml/min/1.73m2. 90 patients 
required renal replacement therapy and 102 patients died. Mean slope decline 
in estimated glomerular filtration rate was -2.8ml/min/1.73m2/year. Median 
follow-up was 8.5 years. Patients who died or required renal replacement 
therapy had significantly higher urinary sodium excretion and urinary 
sodium:creatinine but the association with these parameters and poor 
outcome was not independent of renal function, age and albuminuria. When 
stratified by albuminuria, urinary sodium:creatinine was a significant 
cumulative additional risk for mortality, even in patients with low level 
albuminuria. There was no association between low urinary sodium and risk, 
as observed in some studies. This study demonstrates an association 
between urinary sodium excretion and mortality in chronic kidney disease, 
with a cumulative relationship between sodium excretion, albuminuria and 
reduced survival. These data support reducing dietary sodium intake in 
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chronic kidney disease but further study is required to determine the target 
sodium intake. 
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Introduction  
Experimental and population studies have established dietary sodium intake 
as a key mediator of blood pressure1, with sodium reduction demonstrated to 
result in a fall in systolic blood pressure of 3 to 5 mmHg2, 3. The Trial of 
Hypertension Prevention (TOHP) demonstrated 25% cardiovascular risk 
reduction with a low sodium diet4. Population extrapolations suggest that salt-
related blood pressure elevation accounts for 14% of strokes and 9% of 
myocardial infarctions5. Damaging effects of dietary sodium on end-organs 
have been shown in hypertension, including left ventricular hypertrophy (LVH) 
and albuminuria6-8. However, conflicting data exist, with a Cochrane review 
finding no definitive evidence that sodium intake directly impacted on 
cardiovascular risk9. 
Sodium intake is widely believed to influence progression of chronic kidney 
disease (CKD), independently of effects on blood pressure10. Experimental 
evidence suggests a direct pathogenic role for increased sodium intake in 
renal failure11 and sodium reduction has been shown to reduce proteinuria in 
CKD12, 13.  One Italian study14 showed patients with low urinary sodium 
excretion to have lower baseline creatinine clearance but slower long-term 
progression of CKD. Long term follow-up from the Ramipril in non-diabetic 
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renal failure (REIN) cohort demonstrated that higher urinary sodium:creatinine 
ratio (UNa:Cr) was associated with progression to end stage renal failure15. 
Urinary sodium (UNa) excretion (mmol/24h) is a reliable method of measuring 
sodium intake, independent of dietary assessment, even in patients with 
reduced estimated glomerular filtration rate (eGFR), where 90% of ingested 
sodium is excreted in the urine2. UNa mirrors dietary sodium intake in patients 
with CKD16. The kidney adapts to reduced nephron mass by altering sodium 
handling and increasing fractional excretion of sodium. As overall GFR 
declines with falling nephron mass, there is an increase in single nephron 
GFR, decreased proximal tubular sodium reabsorption and altered capacity of 
the distal tubule to reabsorb sodium17, increasing fractional excretion of 
sodium. Therefore, the kidneys maintain sodium homeostasis between intake 
and excretion.  
Measuring urinary creatinine excretion takes account of muscle mass and 
calculating urinary sodium:creatinine ratio (UNa:Cr) may minimise inaccuracy 
associated with  24-hour collections. One caveat is that lower urinary 
creatinine has been associated with worse outcome18. In this study, we 
assessed whether urinary sodium excretion, corrected for urinary creatinine, 
as a method to maximise the utility of 24-hour urine collection, correlates with 
renal outcome or patient survival in CKD. 
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Patients 
Adult patients attending renal clinics at Glasgow Royal Infirmary between 
1992 and 2007 who had at least one 24-hour urinary sodium measurement 
(UNa) were identified using the electronic patient record. Patients were 
advised to collect urine for 24 hours after the first void. Urinary electrolytes 
were measured using flame photometry in a standard laboratory. The 24-hour 
urinary sodium:creatinine (UNa:Cr) ratio was calculated- as mmol per mmol, 
UNa:Cr has no units. Date of first urinary sodium measurement was deemed 
date of study entry. Trained nurses measured blood pressure manually 3 
times, using standardized sphygmomanometers; the mean of the last 2 
measurements was recorded. Height and weight were recorded. Baseline 
drug therapy, eGFR using the 4-variable MDRD formula, albuminuria as 
urinary albumin:creatinine ratio (uACR) were also recorded. The electronic 
patient record was updated prospectively. General advice was given 
regarding reducing sodium intake, but a dietician did not routinely assess 
patients. Patients receiving renal replacement therapy (RRT) at the time of 
measurement, patients without a weight recording, patients without eGFR 
recording at time of urinary sodium measurement and at least one further 
reading were excluded. Patients with decline in eGFR >10ml/min/1.73m2/yr 
were excluded to provide a cohort with slowly progressive CKD. The West of 
Scotland Ethics committee granted a waiver to approve this study as analysis 
of routinely collected clinical data. 
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Outcomes and analysis 
Dates of starting RRT or death were recorded. Each outcome was analyzed 
separately and together, censoring for death after starting RRT. Annual 
decline in eGFR was calculated. Baseline demographics were compared 
using Student’s t-test, Mann-Whitney U test, Chi-square test or one-way 
analysis of variance (ANOVA) as appropriate with mean values and standard 
deviation (SD) presented for normally distributed data and median and inter-
quartile range (IQR) for non-normally normally distributed data. Correlations 
between urinary sodium measures and other factors were ascertained using 
Spearman or Pearson correlation coefficients. Kaplan-Meier survival analysis 
was performed for time to RRT and or death for patients divided by quartiles 
of UNa:Cr or stratified by group of UNa:Cr and uACR based on the median 
value for each, with significance estimated by the log rank method. Cox 
survival analysis was performed to determine independent predictors of RRT 
and death, with variables identified as significantly influential on outcome by 
univariate analysis entered into a backward stepwise regression model19. 
Different measures of urinary sodium excretion were entered separately 
because of collinearity. Data were analyzed using SPSS version 21 (IBM, 
Armonk, New York), with Kaplan Meier curves drawn with KMWin20 using R 
(R Foundation for Statistical Computing, Vienna, Austria) . 
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Results 
Baseline demographics 
Table 1 summarizes baseline demographics for the cohort. 423 patients were 
included. 50.1% were male with mean age of 51.1 (SD 16.8) years. Online 
data Figure S1 shows the overall cohort with excluded subjects. Mean 
baseline eGFR was 48 (SD 28) ml/min/1.73m2. Mean UNa was 155.8 (SD 
66.0) mmol/24h and mean UNa:Cr 16.4 (SD 5.9). 154 patients had repeat 
UNa available. Median time to repeat sampling was 385 days (IQR 800). 
Repeat UNa correlated with first UNa (R=0.56, p<0.001) with a difference 
between mean first and second UNa of 2.0mmol/24h. Average change in 
urinary sodium was -2.5%. Primary renal disease (PRD) was specified in 199 
(47.0%) patients and was renovascular disease (n=68), diabetic nephropathy 
(n=39), tubulointerstitial disease / polycystic kidney disease (n=51), 
glomerulonephritis (n=39) and others (n=8). The remainder were recorded as 
CKD of unknown cause.  
 
Urinary sodium excretion in patients with CKD 
Patients with lower eGFR had lower UNa levels, particularly in CKD stage 5 
(Figure 1a), although there were significant differences across all CKD groups 
(one way ANOVA p<0.001). UNa:Cr increased with progressive CKD (Figure 
1b). To ascertain factors correlated with urinary sodium excretion, the 
following factors were entered into a correlation matrix: UNa, UNa:Cr, age, 
weight, eGFR, blood pressure, and uACR. UNa correlated with higher weight 
(R=0.37, p<0.001), higher eGFR (0.206, p=0.001), log10uACR (-0.15, 
p=0.003), mean arterial pressure, (0.10, p=0.041) but not systolic blood 
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pressure (SBP) or diastolic blood pressure (DBP). UNa was not significantly 
correlated with age. UNa was higher in men (174 vs. 137mmol/24h, p<0.001). 
UNa was lower in patients prescribed diuretics (mean 145 vs. 159 mmol/24h, 
p=0.05) but there were no significant differences in UNa between those 
receiving and those not receiving ACEi.  
UNa:Cr correlated with age (R=0.30, p<0.001), SBP (0.22, p<0.001), MAP 
(0.12, p=0.02) lower eGFR (-0.23, p<0.001) and higher log10uACR (0.15, 
p=0.003). There were no significant correlations with DBP or weight. UNa:Cr 
was higher in women (17.5 vs. 15.3, p<0.001) and in patients prescribed 
diuretics (p<0.001) but not ACEi.  
 
Urinary sodium and albumin excretion 
To assess to interaction between uACR and UNa:Cr, subjects were divided 
into groups based on ‘high’ or ‘low’, uACR and UNa:Cr respectively with 
subjects allocated to high or low groups based on uACR and/or UNa:Cr being 
above or below the median value for the cohort. The cut points were 
11mg/mmol and 16.0 for uACR and UNa:Cr respectively. The four groups are 
shown in Table 2 with significant differences in age, renal function and blood 
pressure demonstrated across the groups.  
 
Urinary sodium and albumin excretion and need for RRT or death  
90 patients (21.3%) required renal replacement therapy (RRT) and 102 
patients died (24.1%) during follow-up. Cause of death was cardiovascular 
disease (n=25), infection (n=13), malignancy (n=2), known other (n=19), 
unknown (n=43). 48 patients died after receiving RRT. 144 (34.0%) patients 
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either required RRT or died. Censoring for death or RRT, median follow-up for 
the cohort was 8.5 (IQR 6.7) years. Mean slope decline in eGFR was -2.8 
(4.0) ml/min/1.73m2/yr. Characteristics of patients who died or required RRT 
during follow up a shown in data supplement Table S1.  Kaplan-Meier 
analysis demonstrated that highest UNa or UNa:Cr groups exhibited reduced 
patient survival and combined patient and renal survival (p<0.001, data 
supplement Figure S2). Higher UNa:Cr was not associated with significantly 
reduced time to requirement for RRT (p=0.087). Effect of interaction between 
uACR and UNa:Cr was tested using the groups in Table 2. Patients with 
higher UNa:Cr were at greater risk of both death and requirement for RRT, 
irrespective of uACR status (Figure 2b). Increased uACR was an additional 
risk for reduced patient and renal survival (Figure 2). Effect of the interaction 
between UNa:Cr and uACR  on survival analysis  to death, RRT or either 
death or RRT was also performed with patients stratified by diuretic use 
(supplementary Figures S3, S4) or by eGFR above or below 45ml/min/1.73m2 
(supplementary Figure S5). To assess the implications of UNa and 
albuminuria, survival analysis was performed with patients stratified into high 
and low UNa and albuminuria groups based on median UNa (143mmol/24h) 
and uACR (11mg/mmol). In these analyses, patients with lower UNa had 
relatively improved outcome, with patients in higher albuminuria groups 
having poorer outcome (supplementary Figure S6). 
 
Cox regression analyses 
Cox regression analysis was performed to identify independent predictors of 
death, RRT or RRT or death (Table 3 and supplementary Tables S2, S3). 
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Albuminuria, eGFR, and age were independent predictors of death, whilst 
UNa:Cr was not a independent predictor of death (p=0.085). Albuminuria and 
eGFR were predictors of need for RRT whilst eGFR whilst diuretic use 
appeared protective.   Albuminuria and age were predictors of the combined 
outcome of death or RRT.  Additional analyses were performed separately for 
subjects receiving or not receiving diuretic therapy with consistent results 
irrespective of diuretic status (Supplementary Tables S4-9). Figure 3 
demonstrates hazard plots for risk of death or RRT stratified by combined 
UNa:Cr group and albuminuria after adjusting for age, gender, eGFR, MAP, 
diuretic and ACEi usage. This demonstrates association between cumulative 
uACR and UNa:Cr  grouping and significantly increased risk of death or RRT.  
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Discussion 
In this study we demonstrate an association between urinary sodium 
excretion, a marker of dietary sodium intake, and mortality in patients with 
CKD. However, this relationship did not persist after adjusting for age, renal 
function, blood pressure and albuminuria. Urinary sodium was associated with 
risk of requiring RRT, but not independent of albuminuria or baseline eGFR, 
findings similar to post hoc analyses of the REIN studies15.  
The mean sodium excretion in our cohort was equivalent to a dietary salt 
intake of 9.1g per day, lower than the United Kingdom average, reflecting 
combined effects of dietary advice and malnutrition in CKD21. We adjusted 
urinary sodium for urinary creatinine excretion, which corrects for muscle 
mass, but may also take into account reduced GFR, or reduced tubular 
secretion of creatinine in CKD. Use of 24-hour urinary sodium:creatinine ratio 
rather than 24-hour urinary sodium may reduce bias associated with 
incomplete urine collections, similar to using the urinary albumin:creatinine 
ratio to estimate albumin excretion. As urinary albumin:creatinine also 
depends on urinary creatinine, its prognostic role is also determined by low 
urinary creatinine which reflects frailty and low muscle mass. Low urinary 
creatinine may also partly explain the prognostic value of the UNa:Cr ratio in 
our study. 24-hour urine collection remains the best method for assessing 
sodium excretion and our sodium:creatinine ratio was derived from a 24-hour 
collection. Spot samples are less representative due to circadian variation in 
sodium excretion.  
We observed lower urinary sodium excretion in patients with lower eGFR 
perhaps due to reduced dietary intake related to poor appetite. Alternatively, 
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despite increasing fractional sodium excretion, the failing kidneys may be 
unable to excrete sodium fully. However, even if sodium is stored in non-
osmotically active form, as recently proposed22, accumulation of vast amounts 
of sodium over a prolonged period would overwhelm storage sites. Thus even 
in advanced CKD, patients are in sodium balance and UNa reflects dietary 
intake. 
There are multiple mechanisms for sodium-mediated damage. 
Haemodynamic effects mediated via volume retention include increased 
shear stress, endothelial dysfunction, elevated cardiac preload, vascular 
stiffness and elevated afterload and LVH. Non-haemodynamic factors such as 
oxidative stress via superoxide production23 and inflammation have also been 
demonstrated24, 25.  
Damaging effects of dietary sodium intake on end-organs have been shown in 
various populations. A study of normotensive and never treated hypertensives 
showed high dietary sodium intake was associated with LVH and 
albuminuria6. The Framingham Offspring Study demonstrated increasing 
urinary sodium to be associated with increasing uACR7, 8, using spot urinary 
sodium samples normalized to creatinine. Using spot samples could introduce 
variability as urinary sodium excretion may vary throughout the day. The large 
Scottish Heart Health Study, drawn from a similar population to ours, showed 
that urinary sodium predicted coronary heart disease in women26.  
Controversy exists regarding the influence of very low sodium intake on 
cardiovascular events in the general population. A large pan-European study 
in patients without cardiovascular disease found low urinary sodium excretion 
to be associated with increased cardiovascular risk27. Post hoc analyses of 
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the ONTARGET and TRANSCEND trials in patients at high cardiovascular 
risk demonstrated J-shaped relationships between urinary sodium and 
outcome28, whilst data from ONTARGET suggest that sodium intake does not 
per se increase risk of CKD in diabetics29. Therefore in non-CKD populations, 
whilst reduction in dietary sodium intake may be beneficial, there may be a 
lower threshold of optimum sodium intake.  
In patients with CKD, proteinuria (or albuminuria) is major predictor of both 
CKD progression30 and predicts cardiovascular disease in both CKD and the 
general population31, 32. In univariate analyses, we have demonstrated 
increased urinary sodium excretion has cumulative effects with albuminuria on 
both renal and patient survival, in patients with low and high urinary albumin 
excretion. Lowering dietary sodium intake has been shown to reduce 
proteinuria, independent of blood pressure12. The anti-proteinuric response to 
renin-angiotensin system inhibitors is augmented by a low sodium diet33. A 
recent crossover study has shown salt restriction to have dramatic effects on 
blood pressure, vascular function and proteinuria in CKD patients34. These 
results provide powerful arguments for salt restriction in CKD. Although 
observational, our study adds weight to the notion that sodium restriction is 
beneficial.  A prospective randomized controlled trial in optimally treated CKD 
patients is required, addressing effects of reduced sodium intake on mortality, 
cardiovascular events and commencement of renal replacement therapy.  
Our study has several limitations. This was a retrospective cohort study using 
prospectively collected data.  Patients were prescribed a number of different 
medications. Variations in diet during follow-up are not accounted for, but in a 
subset of patients with two collections, urinary sodium was relatively constant 
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over time. An assessment of nutritional status would be useful. We do not 
have causes of death for all patients. Despite attempting to ensure complete 
urinary collections, some may be incomplete. As an observational study we 
report associations and cannot prove causality. There may be co-linearity 
between some of the variables in the multivariate model. We have not 
assessed the impact of sodium intake on non-fatal cardiovascular events. As 
low urinary creatinine is a major component of poor outcome and it is difficult 
to dissociate any relationship between UNa:Cr, urinary ACR and outcome and 
that driven solely by urinary creatinine18. A larger study would be required to 
prove this. Nonetheless, UNa:Cr represents a useful marker for monitoring 
sodium intake and may be a target for interventional studies examining long-
term effect of sodium reduction in CKD. 
 
Perspectives 
A high 24-hour urinary sodium to creatinine ratio, reflective of proportionally 
high dietary sodium intake in CKD, is associated with significantly increased 
risk of death but not independent of eGFR, age and albuminuria. There is a 
cumulative relationship between urinary sodium:creatinine ratio and 
albuminuria on adverse outcomes. These are novel findings and the first to 
observe a relationship between sodium intake and mortality in CKD. Further 
long-term studies to determine optimal sodium intake in CKD are required.  
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Novelty and Significance 
What Is New? 
• Urinary sodium to creatinine ratio is higher with increasing severity of chronic 
kidney disease 
• High urinary sodium intake reflected by a high urinary sodium or high urinary 
sodium to creatinine ratio is associated with reduced survival in chronic kidney 
disease patients irrespective of albuminuria status 
• Association between high urinary sodium or high urinary sodium to creatinine 
ratio and increased need for renal replacement therapy is not independent of 
baseline renal function or albuminuria 
What Is Relevant? 
• These data support the notion of reducing dietary sodium intake in patients 
with chronic kidney disease 
• The major benefit of sodium reduction is likely to be on patient survival and 
not on progression of renal disease 
• Further study is required to inform target levels of sodium intake in patients 
with chronic kidney disease 
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Summary 
We have demonstrated an association between urinary sodium excretion and 
mortality in chronic kidney disease and a cumulative relationship between sodium 
excretion, albuminuria and reduced survival.  
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Table and figure legends 
 
Figure 1 (a) Bar chart of mean urinary sodium excretion (mmol/24h) and 1SD by 
CKD stage, p<0.001 by one-way ANOVA (b) Bar chart of mean UNa:Cr and 1SD by 
CKD stage, p<0.001 by one-way ANOVA.  
Figure 2 (a) Kaplan-Meier survival plot of time to death by group of UNa:Cr  and 
albuminuria (b) Kaplan-Meier survival plot of survival to requirement for RRT by 
group of UNa:Cr  and albuminuria (1 = low UNa:Cr, low uACR, 2 = high UNa:Cr, low 
uACR, 3 = low UNa:Cr, high uACR, 4 = high UNa:Cr, high uACR). Comparison by 
log rank test and estimate of significance, for both (a) and (b) p<0.001.  
Figure 3 Hazard plot of risk of death or RRT by combined UNa:Cr  and albuminuria 
(1 = low UNa:Cr, low uACR, 2 = high UNa:Cr, low uACR, 3 = low UNa:Cr, high 
uACR, 4 = high UNa:Cr, high uACR) after adjusting for age, gender, eGFR, 
proteinuria, MAP and diuretic or ACEi usage. Variables included in the Cox 
regression model were age, eGFR, gender, mean arterial pressure, log10uACR, 
UNa:Cr, ACEi use, diuretic use.  
 
Table 1: Baseline demographics of cohort. 
Mean ± SD or median (IQR) values are displayed or number and percentage of total 
cohort. eGFR = estimated glomerular filtration rate; SBP = systolic blood pressure; 
DBP = diastolic blood pressure; MAP =mean arterial pressure; uACR = urinary 
albumin to creatinine ratio; UNa = 24h urinary sodium excretion; UNa:Cr = urinary 
sodium to creatinine ratio; UCr = 24h urinary creatinine excretion; ACEi = 
angiotensin converting enzyme inhibitor; RRT = renal replacement therapy. 
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Table 2: Demographics of patients by stratum of combined urinary sodium: 
creatinine and urinary albumin: creatinine ratio  
Subjects were divided into groups based on ‘high’ or ‘low’, urinary albumin excretion 
and UNa:Cr respectively with subjects allocated to high or low groups based on 
uACR and/or UNa:Cr being above or below median value for the cohort- 11mg/mmol 
and 16.0 for ACR and UNa:Cr respectively.  Data shown are mean with standard 
deviation in parentheses for continuous variables and number and percentage of the 
group for categorical variables.  Comparisons are one-way ANOVA for continuous 
variables and Chi-square for categorical variables. UNa:Cr = urinary sodium to 
creatinine ratio; uACR = urinary albumin to creatinine ratio; eGFR = estimated 
glomerular filtration rate; SBP = systolic blood pressure; MAP =mean arterial 
pressure; log10ACR = log transformed uACR; UNa = 24h urinary sodium excretion; 
UCr = 24h urinary creatinine excretion; RRT = renal replacement therapy 
Table 3: Cox regression survival analyses for end point of death 
Data presented as hazard ratio (HR), 95% confidence interval (95% CI) and estimate 
of significance (p). eGFR = estimated glomerular filtration rate; log10ACR = log 
transformed urinary albumin:creatinine ratio; age in years; MAP = mean arterial 
pressure; UNa:Cr = urinary sodium:creatinine ratio; ACEi = angiotensin converting 
enzyme inhibitor (0=yes). Variables included in the Cox regression model were age, 
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eGFR, gender, mean arterial pressure, log10uACR, UNa:Cr, ACEi use, diuretic use. 
 
Figure 1 
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Figure 2 
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Figure 3
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Table 1 
Variable Result 
 
 
Gender (% male) 212 (50.1) 
Age (years) 51.1 ± 16.8 
Weight  75.5 ± 18.4 
eGFR at baseline (ml/min/1.73m2) 48 ± 25 
SBP (mmHg) 139 ± 25 
DBP (mmHg) 79 ± 13 
MAP (mmHg) 99 ± 14 
uACR (mg/mmol)  11.0 (83) 
UNa (mmol/24h) 155.8 ± 66.0 
UCr (mmol/24h) 10.1 ± 3.9 
UNa:Cr  16.4 ± 5.9 
Diuretic therapy (%) 106 (25.1) 
ACEi (%) 105 (24.8) 
Deaths (n,%) 102 (24.1) 
RRT (n,%) 90 (21.3%) 
eGFR loss (ml/min/1.73m2/yr) -2.8 (4.0) 
 
 30 
Table 2 
Variable 
All patients 
N=423 
Low UNa:Cr 
Low uACR 
N=127 
High UNa:Cr 
Low uACR 
N=111 
Low UNa:Cr 
High uACR 
N=80 
HIgh UNa:Cr 
High uACR 
N=105 
p 
eGFR (ml/min/1.73m2) 48 (25) 61 (21) 54 (23) 36 (23) 34 (22) <0.001 
Age (y) 52.1 (16.8) 46.9 (16.5) 52.7 (17.8) 51.9 (14.6) 57.9 (15.8) <0.001 
n male (%) 212 (50.1) 73 (57.5) 42 (37.8) 52 (65.0) 45 (42.9) <0.001 
SBP (mmHg) 139 (24) 132 (20) 136 (22) 142 (25) 150 (26) <0.001 
MAP (mmHg) 99 (14) 96 (13) 96 (13) 102 (15) 105 (16) <0.001 
log10uACR 1.14 (0.9) 0.39 (0.40) 0.47 (0.44) 1.99 (0.37) 2.05 (0.43) <0.001 
Weight 75.5 (18.4) 75.3 (17.1) 74.2 (20.0) 79.2 (18.4) 74.3 (17.8) 0.23 
UNa (mmol/24h) 156 (66) 140 (46) 192 (82) 127 (46) 160 (64) <0.001 
UCr (mmol/24h) 10.1 (3.9) 12.0 (3.7) 9.4 (3.6) 10.7 (3.8) 7.9 (3.2) <0.001 
Dead (n) (% of group) 102 (24.1) 9 (7.1) 24 (21.6) 27 (33.8) 45 (42.9) <0.001 
RRT (n) (% of group) 90 (21.3) 8 (6.3) 7 (6.3) 28 (35.0) 47 (44.8) <0.001 
RRT or dead (n)(% of group) 144 (34.0) 14 (11.0) 24 (21.6) 40 (50.0) 66 (62.9) <0.001 
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Table 3 
 
 
Death as the dependent variable (n=102) 
 
Variable Univariate Multivariate 
 
 HR p-value 95% Confidence interval HR p-value 95% Confidence interval 
Age 1.049  1.030 1.069 1.048 <0.001 1.030 1.067 
log10 uACR 1.767 <0.001 1.303 2.396 1.726 <0.001 1.281 2.325 
eGFR 0.976 0.001 0.962 0.989 0.973 <0.001 0.961 0.986 
UNa:Cr 1.034 0.057 0.999 1.071 1.030 0.085 0.996 1.064 
MAP 0.993 0.32 0.978 1.007     
Diuretic use 1.209 0.42 0.761 1.922     
 ACEi use 1.155 0.53 0.738 1.806     
Gender(female)  0.879 0.55 0.578 1.337     
 
 
 
 
